

# PCSK9 Antibody (C-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7333b

### **Specification**

#### PCSK9 Antibody (C-term) - Product Information

Application WB, IHC-P, FC,E

Primary Accession
Reactivity
Host
Clonality
Isotype
Antigen Region

O8NBP7
Human
Rabbit
Polyclonal
Rabbit Ig
479-508

PCSK9 Antibody (C-term) - Additional Information

#### **Gene ID 255738**

#### **Other Names**

Proprotein convertase subtilisin/kexin type 9, 3421-, Neural apoptosis-regulated convertase 1, NARC-1, Proprotein convertase 9, PC9, Subtilisin/kexin-like protease PC9, PCSK9, NARC1

## **Target/Specificity**

This PCSK9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 479-508 amino acids from the C-terminal region of human PCSK9.

# Dilution

WB~~1:1000 IHC-P~~1:100 FC~~1:10~50


#### **Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.


#### Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

### **Precautions**



Western blot analysis of lysate from Hela cell line, using PCSK9 Antibody (C-term)(Cat. #AP7333b). AP7333b was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 35ug.



Western blot analysis of lysate from HepG2 cell line, using PCSK9 Antibody (C-term)(Cat. #AP7333b). AP7333b was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody.



PCSK9 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

PCSK9 Antibody (C-term) - Protein Information

Name PCSK9

Synonyms NARC1

#### **Function**

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:<a href="http://ww w.uniprot.org/citations/18039658" target=" blank">18039658</a>). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:<a href= "http://www.uniprot.org/citations/18799458 "target=" blank">18799458</a>,

PubMed:<a href="http://www.uniprot.org/ci tations/17461796"

target=" blank">17461796</a>,

PubMed:<a href="http://www.uniprot.org/ci tations/18197702"


target=" blank">18197702</a>,

PubMed:<a href="http://www.uniprot.org/ci tations/22074827"


target="\_blank">22074827</a>). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:<a href="http://www.uniprot.org/c itations/18660751"

target="\_blank">18660751</a>). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related

Lysate at 20ug.



PCSK9 Antibody (C-term) (RB18880) IHC analysis in formalin fixed and paraffin embedded human Colon carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the PCSK9 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.



Immunohistochemical analysis of paraffin-embedded H.colon carcinoma section using PCSK9 Antibody (C-term)(Cat#AP7333b). AP7333b was diluted at 1:100 dilution. A peroxidase-conjugated goat anti-rabbit IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.



anti-apoptotic signaling pathways.

#### **Cellular Location**

Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Note=Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein Localizes to the endoplasmic reticulum in the absence of LDLR and colocalizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation


#### **Tissue Location**

Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells

# PCSK9 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture



PCSK9 Antibody (C-term) (Cat. #AP7333b) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

## PCSK9 Antibody (C-term) - Background

PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. The protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons.

# PCSK9 Antibody (C-term) - References

Abifadel,M., Rabes,J.P. Hum. Mutat. 30 (7), E682-E691 (2009) McNutt,M.C., Kwon,H.J. J. Biol. Chem. 284 (16), 10561-10570 (2009) Shioji,K., Mannami,T. J. Hum. Genet. 49 (2), 109-114 (2004) Abifadel,M., Varret,M. Nat. Genet. 34 (2), 154-156 (2003)